How to develop novel treatments for EGFR-mutant lung cancer.
Division of Medical Oncology, Cannizzaro Hospital, Via Messina 829, 95126, Catania, Italy.
Giuseppe Luigi
GL
Banna
Division of Medical Oncology, University Hospital of Parma, Via Gramsci, 14 43126 Parma, Italy.
Marcello
M
Tiseo
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
EGF receptor; circulating tumor-derived DNA; liquid biopsy; non-small-cell lung cancer; repeated biopsy; tumor heterogeneity; tyrosine kinase inhibitors